http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
-
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
-
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
-
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
-
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Organon (OGN) and Eli Lilly (LLY) Enter Commercialization Agreement in Europe for Two Migraine Medicines
-
Lilly (LLY) says Zepbound achieved additional 6.7% weight loss following a 36-week open-label lead-in period
-
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
-
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
-
FDA Approves Lilly's (LLY) Zepbound for Chronic Weight Management
-
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
-
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh
-
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
-
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Pr
-
Eli Lilly & Co. (LLY) reports ~80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab monthly maintenance dosing at two years
-
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
-
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
-
Eli Lilly & Co. (LLY) Reports Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
-
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
-
Lilly Announces Details of Presentations at ESMO Congress 2023
-
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Eli Lilly & Co. (LLY) Announces Retirement of Mike Mason, President of Lilly Diabetes and Obesity
-
Lilly Announces Leadership Transitions
-
Eli Lilly & Co. (LLY) to Acquire POINT Biopharma (PNT) for $12.50/sh Cash or $1.4B
-
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
-
Eli Lilly & Co. (LLY) announced FDA CRL related to lebrikizumab BLA for eczema
-
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
-
Eli Lilly & Co.'s (LLY) Jardiance approved by FDA for adults with chronic kidney disease
-
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
-
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
-
Eli Lilly & Co. (LLY) Reports Retevmo Demonstrates Superior Progression-Free Survival
-
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
-
Lilly Completes Acquisition of Versanis Bio
-
Eli Lilly & Co. (LLY) completes takeover of Sigilon Therapeutics (SGTX)
-
Lilly Completes Acquisition of Sigilon Therapeutics
-
Eli Lilly & Co. (LLY) Completes Acquisition of DICE Therapeutics (DICE)
-
Lilly Completes Acquisition of DICE Therapeutics
-
Eli Lilly, UPS ahead, SoftBank's surprise loss - what's moving markets
-
Eli Lilly & Co. (LLY) Reports Results from LIBRETTO-431 Study of Retevmo
-
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advance
-
Eli Lilly & Co. (LLY) Reports Tirzepatide Demonstrated Significant and Superior Weight Loss Compared to Placebo in Two Studies
-
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
-
Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement
-
Eli Lilly & Co. (LLY) Extends Tender Offer to Acquire DICE (DICE)
-
Lilly Announces Extension of Tender Offer to Acquire DICE
-
Lilly (LLY) Announces Results from Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
-
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
-
Sangamo Therapeutics (SGMO) Announces Research Evaluation and Option Agreement With Subsidiary of Lilly (LLY) for Novel Engineered Capsids
